Results of MAIC study comparing pirtobrutinib ... - CLL Support

CLL Support

23,258 members39,957 posts

Results of MAIC study comparing pirtobrutinib vs venetoclax in CLL patients previously treated with a covalent BTK inhibitor

7 Replies

You need to be a member of this community to see this post.

Read more about...
7 Replies

You need to be a member of this community to see hidden responses.

Not what you're looking for?

You may also like...

YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in

Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

3rd April 2020 Blood Key points to note: BTK inhibitor therapy achieves durable disease...
Jm954 profile image
Administrator

Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

We've heard that re-treatment with venetoclax is possible. Per the attached image, here's some...
AussieNeil profile image
Partner

VenR in Relapsed CLL: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from MURANO 3 study

This is an important evaluation and insight into how your CLL profile affects your response to VR...
Jm954 profile image
Administrator